virus
ultramicroscop
acellular
metabol
inert
nucleoprotein
particl
either
deoxyribonucl
acid
dna
ribonucl
acid
rna
without
lipid
envelop
oblig
intracellular
parasit
util
host
cell
machineri
propag
caus
ailment
benign
common
wart
irrit
cold
deadli
bloodi
african
fever
entri
viru
specif
host
cell
depend
precis
attach
fit
viral
surfac
molecul
molecul
host
cell
viral
strain
uniqu
surfac
antigen
structur
host
cell
receptor
life
cycl
thu
adopt
variou
invas
strategi
infect
everi
form
life
due
genet
variat
mode
transmiss
effect
replic
abil
persist
within
host
virus
caus
widespread
diseas
bacteria
human
thu
develop
antivir
drug
requir
great
effort
sever
report
discoveri
new
drug
tradit
medicin
indic
use
medicin
plant
potenti
sourc
antivir
drug
develop
sever
report
indic
wide
varieti
phytochem
includ
alkaloid
flavonoid
terpenoid
polyphenol
coumarin
lignan
therapeut
applic
due
interfer
viral
entri
replic
along
antioxid
properti
differ
vitro
vivo
bioassay
phytochem
lead
identif
potenti
antivir
molecul
chapter
summar
scientif
approach
use
valid
potenti
antivir
lead
select
genet
function
divers
viral
famili
crude
extract
pure
compound
indepth
studi
common
vitro
antivir
assay
test
efficaci
mode
molecular
mechan
action
describ
vivo
method
select
virus
viral
infect
control
strategi
includ
public
health
measur
minim
risk
infect
vaccin
expos
individu
antiinfect
drug
infect
individu
public
health
measur
safe
drink
water
prevent
polio
rota
viru
infect
pest
control
prevent
arthropod
rodentborn
yellow
fever
dengu
enceph
hanta
arena
virus
howev
provid
benefit
peopl
underdevelop
develop
world
challeng
second
challeng
discov
mean
control
airborn
respiratori
infect
public
health
measur
never
total
effect
vaccin
second
strategi
although
vaccin
dramat
decreas
incid
polio
yellow
fever
rabi
measl
mump
rubella
hepat
b
yet
effect
human
immunodefici
viru
hiv
herp
simplex
viru
hsv
hepat
c
viru
hcv
influenza
includ
common
cold
caus
strain
rhinovirus
develop
polyval
vaccin
virus
also
challeng
moreov
alpha
filoviru
ebola
caus
devast
epidem
sporad
outbreak
difficult
vaccin
entir
popul
erad
thu
infect
occur
despit
best
effort
humankind
henc
antivir
drug
develop
scientist
look
featur
ideal
antivir
drug
effect
inhibit
essenti
viral
process
prevent
develop
drugresist
virus
broad
activ
singl
drug
common
cold
virus
minimum
effect
host
system
first
featur
obviou
remain
depend
viral
process
target
till
antivir
approv
us
food
drug
administr
although
mani
viral
diseas
effect
drug
moreov
sever
viral
diseas
requir
longterm
treatment
usual
lead
develop
drugresist
virus
exist
antivir
nucleosid
analog
act
antimetabolit
dna
synthesi
prevent
viral
replic
infect
cell
relat
nucleotid
analog
use
hepat
b
viru
hbv
hcv
hsv
hiv
infect
cell
analog
incorpor
replic
dna
strand
phosphoryl
chain
termin
stop
viral
dna
polymeras
activ
affect
mitochondri
dna
lead
advers
effect
bone
marrow
suppress
anoth
famili
synthet
nucleosid
analog
reversetranscriptas
rt
inhibitor
help
design
drug
preferenti
activ
nucleosid
analog
act
nucleosid
analog
reversetranscriptas
inhibitor
polymeras
inhibitor
hbv
thu
antivir
nucleotid
analog
repress
viral
reproduct
interf
viral
nucleic
acid
replic
compet
natur
deoxynucleotid
triphosph
dntp
ntp
substrat
incorpor
nascent
viral
nucleic
acid
lead
chain
termin
mutagenesi
tabl
extens
longterm
clinic
use
antivir
acyclovir
refer
treatment
herp
virus
result
emerg
drugresist
strain
due
mutat
viral
thymidin
kinas
andor
dna
polymeras
along
renal
impair
antivir
drug
viru
specif
target
orient
requir
appropri
diagnosi
therapeut
intervent
anoth
factor
avail
suitabl
vaccin
degre
effect
particular
viru
vaccin
effect
approach
prevent
diseas
howev
despit
continu
advanc
medic
scienc
viral
diseas
major
caus
death
around
globe
develop
antivir
drug
depend
uniqu
featur
hosteviru
interact
virus
acellular
hostand
routespecif
infect
nucleic
acid
regul
host
cell
dna
multipl
oblig
intracellular
parasit
viral
replic
depend
metabol
pathway
host
thu
design
effect
antivir
drug
target
virusspecif
enzym
replic
step
without
affect
host
cell
difficult
advanc
molecular
biolog
genet
help
design
ration
approach
develop
antivir
agent
target
specif
sitesstep
viral
life
cycl
includ
inactiv
extracellular
viru
particl
prevent
viral
attach
fusion
entri
penetr
replic
viral
genom
synthesi
viralspecif
protein
intermedi
assembl
releas
new
virion
howev
desir
target
inhibit
major
viral
enzym
essenti
replic
spread
diseas
wellstudi
inhibitor
hiv
hsv
influenza
virus
target
host
cell
bind
betulin
acid
uncoat
capsid
amantadin
pleconaril
viral
replic
rt
inhibitor
zidovudin
abacavir
nevirapin
viral
enzym
integras
dnarna
polymeras
acyclovir
cidofovir
ribavirin
proteinas
polyprotein
precursor
assembl
matur
indinavir
ritonavir
rimantadin
basi
strategi
sever
compound
test
differ
virus
licens
antivir
approv
till
moreov
studi
viral
genom
gene
function
regul
led
ration
design
genebas
drug
induc
protect
antivir
immun
interfer
viral
replic
gene
express
viral
messeng
rna
limit
deliveri
site
replic
nucleas
degrad
histori
human
civil
reveal
almost
ancient
cultur
reli
upon
medicin
plant
treat
ailment
bodi
mind
world
popul
use
tradit
medicin
primari
health
care
discoveri
synthet
drug
better
efficaci
quick
recoveri
mani
diseas
lead
sever
advers
effect
longterm
clinic
use
particularli
chronic
difficulttotreat
diseas
thu
huge
upsurg
use
natur
product
prevent
treat
seriou
viral
diseas
howev
herbal
product
qualiti
control
unabl
provid
consist
result
even
produc
undesir
effect
modernday
anticanc
antimicrobi
drug
root
tradit
medicin
till
bare
analyz
tip
iceberg
design
drug
plant
henc
utmost
import
search
phytochem
antivir
potenti
unexplor
plant
use
ethnomedicin
lose
herbal
resourc
due
rapid
anthropogen
activ
includ
industri
urban
mani
virus
uniqu
featur
structur
replic
cycl
may
act
potenti
target
design
new
antivir
evid
acyclovir
acycloguanosin
block
certain
enzym
herp
virus
respons
trigger
diseas
due
structur
divers
broad
rang
bioactiv
ethnomedicin
serv
sourc
complementari
antivir
inhibit
specif
enzym
step
viral
replic
cellular
factor
tabl
mani
dnarna
virus
ayurveda
tradit
chines
medicin
particular
use
sever
medicin
plant
reduc
diseas
sever
mani
antivir
activ
research
antivir
potenti
plant
first
start
plant
found
effect
influenza
past
year
numer
broadbas
screen
program
antivir
activ
medicin
plant
initi
use
vitro
vivo
assay
british
colombian
medicin
plant
show
activ
corona
virus
respiratori
syncyti
viru
rsv
para
influenza
hsv
marin
alga
spirulina
show
antimutagen
immunomodulatori
antivir
activ
interestingli
cyanovirin
n
protein
blue
green
alga
inactiv
bind
sulfat
polysaccharid
seawe
alga
show
antihiv
antihsv
activ
list
select
medicin
plant
compound
antivir
activ
common
viral
diseas
present
tabl
structur
import
compound
depict
figur
vitro
assay
preliminari
step
toward
identif
antivir
activ
plant
extract
phytocompound
assay
measur
abil
viru
infect
replic
specif
cell
line
respons
particular
extract
toward
relev
viru
infect
cell
cultur
system
provid
rapid
less
cumbersom
method
growth
virus
higher
titer
test
cytotox
antivir
efficaci
mainten
cultur
genet
manipul
cell
line
character
routin
use
common
virus
along
respect
method
given
tabl
ophiorrhiza
nicobarica
rubiacea
harmalin
inhibit
ie
gene
synthesi
rhu
javanica
anacardiacea
moron
acid
achyranth
aspera
amaranthacea
oleanol
acid
odina
wodier
anacardiacea
chlorogen
acid
prevent
attach
mallotu
peltatu
euphorbiacea
ursol
acid
hsv
replic
terminalia
chebula
combretacea
chebulag
acid
punicalagin
inhibit
entri
cell
spread
ilex
gentiana
lutea
gentianacea
e
antirsv
cimicifuga
foetida
l
ranunculacea
cimicifugin
inhibit
viral
attach
intern
hbv
artemisia
capillari
asteracea
z
inhibit
hbv
dna
replic
aster
tataricu
l
asteracea
astataricuson
astataricusol
inhibit
hbv
dna
replic
swertia
macrosperma
gentianacea
swermacrolacton
luteolin
inhibit
secret
hbv
surfac
antigen
piper
longum
linn
piperacea
piperin
inhibit
secret
hbv
surfac
antigen
phyllanthu
niruri
l
phyllanthacea
nirtetralin
antihbv
activ
hcv
morinda
citrifolia
rubiacea
pyropheophorbid
pheophorbid
inhibit
entri
postentri
step
hcv
syncephalastrum
racemosum
syncephalastracea
ursol
acid
antihcv
activ
marrubium
peregrinum
l
lamiacea
ladanein
hcv
entri
inhibitor
acacia
nilotica
fabacea
e
antihcv
activ
vaccinium
virgatum
aiton
ericacea
proanthocyanidin
inhibit
hcv
replic
figur
initi
evalu
usual
done
twofold
concentr
differ
eg
ngml
mgml
h
cultur
confluenc
appropri
cell
line
ad
test
drug
placebo
immedi
viru
infect
drug
effect
test
pretreat
cell
need
treat
test
drug
min
viru
infect
incub
uninfect
cell
monolay
treat
test
drug
provid
idea
maximum
dose
drug
caus
minimum
cell
toxic
enlarg
granular
round
detach
etc
degre
cytotox
toxic
pvh
partial
heavi
toxic
ph
partial
heavi
toxic
p
partial
toxic
ps
partial
slightli
toxic
nontox
cell
inhibitori
cytotox
concentr
cc
end
point
viru
inhibitori
effect
concentr
ec
determin
graph
plot
concentr
versu
cellular
effect
due
viru
infect
select
therapeut
index
si
ti
calcul
cc
ec
anoth
rapid
sensit
vitro
assay
evalu
antivir
agent
base
spectrophotometr
assess
viabil
virusinfect
mockinfect
cell
via
situ
reduct
tetrazolium
dye
bromid
mtt
mt
equal
sensit
plaqu
reduct
assay
mechan
base
convers
yellow
watersolubl
dye
mtt
mt
purpl
color
insolubl
formazan
crystal
mitochondri
enzym
viabl
cell
quantit
amount
formazan
produc
well
determin
spectrophotometr
nm
subtract
background
absorpt
plate
nm
cytotox
test
drug
need
evalu
plate
data
analysi
statist
softwar
program
use
determin
efficaci
ec
cell
toxic
cc
si
ti
test
drug
method
allow
screen
larger
number
extractcompound
time
simplifi
procedur
protocol
cell
monolay
ml
cultur
column
flatbottom
plate
cellsml
need
ad
twofold
dilut
test
drug
h
eight
concentr
serumfre
medium
medium
remov
assay
use
detect
antivir
activ
test
drug
cytopath
express
microscop
valid
antivir
potenti
herbal
ethnomedicin
ad
viru
multipl
infect
moi
six
well
row
uninfect
control
row
ad
media
adsorpt
min
c
unabsorb
virus
remov
wash
fresh
media
infect
cell
mix
test
drug
concentr
well
incub
c
co
incub
h
remov
drugcontain
media
ml
mtt
solut
mgml
phosphat
buffer
salin
pb
ad
fresh
media
ml
well
incub
h
c
final
medium
replac
dimethyl
sulfoxid
dmso
ml
dissolv
formazan
min
glycin
buffer
ml
mix
well
ph
absorb
read
nm
usual
result
calcul
plot
graph
absorb
yaxi
versu
drug
concentr
xaxi
column
viru
serv
cell
viabil
control
well
column
viru
without
drug
serv
virusinduc
loss
cell
viabil
row
column
increas
concentr
drug
without
viru
provid
ic
cell
inhibitori
concentr
drug
ec
ec
deduc
plot
absorb
virusinfect
well
column
row
versu
concentr
drug
show
increas
absorb
viru
alon
neutral
antibodi
assay
use
simian
immunodefici
viru
siv
simianhiv
done
tzmbl
cell
reflect
reduct
tatinduc
luciferas
luc
report
gene
express
singl
round
viru
infect
tzmbl
cell
hela
cell
clone
engin
express
cluster
differenti
cec
chemokin
receptor
type
contain
integr
report
gene
firefli
luciferas
escherichia
coli
bgalactosidas
control
long
termin
repeat
thu
highli
sensit
prone
infect
immunodefici
virus
includ
primari
isol
clone
envpseudotyp
virus
diethylaminoethyl
deae
dextran
use
enhanc
infect
neutral
soon
infect
report
gene
express
induc
viral
transactiv
protein
tat
luciferas
activ
quantifi
luminesc
directli
proport
number
infecti
viru
particl
present
initi
inoculum
highthroughput
assay
requir
plate
clonal
cell
provid
enhanc
precis
uniform
valid
singleround
infect
either
unclon
virus
grown
human
lymphocyt
molecularli
clone
envpseudotyp
virus
produc
transfect
cell
protocol
tzmbl
cell
well
usual
seed
plate
incub
overnight
separ
vial
moi
virion
mix
test
drug
vehicl
h
c
ad
tzmbl
cell
incub
h
wash
cell
cold
pb
fresh
media
test
drug
ad
cultur
h
use
untreat
infect
cell
neg
azidothymidin
azt
treat
cell
posit
control
cell
need
wash
twice
pb
lyse
lysi
buffer
supernat
ad
substrat
analyz
luciferas
activ
optipl
use
fluorimet
result
express
percentag
inhibit
luminesc
experiment
group
test
drug
azt
luminesc
infect
cell
without
drug
x
percent
inhibit
calcul
subtract
valu
cellbas
assay
cemgreen
fluoresc
protein
gfp
stabl
tcell
linecontain
plasmid
encod
gfp
suitabl
moi
cultur
postinfect
cell
well
incub
test
drug
day
use
azt
solvent
use
prepar
test
drug
control
virusinfect
cell
lyse
promega
cell
lysi
buffer
ml
transfer
cultur
plate
read
absorb
nm
excit
nm
emiss
mean
fluorimet
result
express
percentag
inhibit
gfp
fluoresc
experiment
groupfluoresc
infect
cell
without
test
drug
x
percent
inhibit
calcul
subtract
valu
gener
use
confirm
result
cpe
reduct
inhibit
assay
freshli
prepar
test
drug
show
activ
initi
experi
day
test
cell
lyse
freezeethaw
cycl
elut
virion
centrifug
g
result
supernat
increas
drug
concentr
titrat
infecti
virion
subject
fresh
cpe
inhibit
test
briefli
cell
plate
plate
suscept
cell
line
need
incub
h
ad
serial
dilut
viru
prepar
drugtreat
cell
develop
cpe
indic
presenc
infecti
viru
effect
concentr
ec
test
drug
determin
concentr
inhibit
viru
yield
one
log
infecti
viru
yield
assay
pretreat
posttreat
test
method
valid
antivir
activ
plant
drug
reduc
viru
infect
tcid
ml
calcul
assay
secondari
test
potenti
antivir
compound
antivir
activ
test
compound
express
ti
si
determin
divid
cc
ec
gener
si
consid
potenti
antivir
agent
although
low
si
posit
control
need
consid
compound
si
valu
need
evalu
addit
viru
strain
establish
full
spectrum
activ
potenti
antivir
drug
need
screen
direct
assay
measur
viral
replic
titer
inhibit
direct
assay
measur
reduct
viral
titer
presenc
test
drug
compar
untreat
cell
cpe
inhibit
determin
end
point
titrat
evalu
virucid
activ
preincub
viru
plu
test
compound
fifti
percent
end
point
titrat
done
confluent
monolay
cellswel
infect
serial
dilut
tcid
ml
viru
suspens
plate
adsorpt
h
c
test
drug
serial
twofold
dilut
ad
mainten
medium
fetal
bovin
serum
fb
plu
antibiot
incub
c
record
viral
cpe
light
microscop
day
viru
control
uninfect
drugtreat
untreat
cell
control
cytotox
test
agent
concentr
kill
cell
monolay
viru
titer
determin
antivir
activ
inhibit
viru
titer
maximum
nontox
dose
highest
concentr
test
drug
without
affect
cell
morpholog
antivir
activ
need
present
least
two
subsequ
dilut
test
agent
otherwis
activ
virucid
due
toxic
test
drug
extracellular
virucid
activ
also
determin
titrat
residu
infecti
viru
particl
incub
test
drug
viru
suspens
tcid
ml
h
c
assay
use
quantit
estim
virus
antibodi
avail
either
commerci
inhous
unabl
differenti
infecti
noninfecti
viral
particl
briefli
untreat
drugtreat
cell
infect
known
amount
viru
moi
adsorpt
min
unabsorb
viru
particl
remov
wash
ad
fresh
media
incub
h
time
requir
achiev
cpe
cell
need
rewash
pb
fix
paraformaldehyd
wash
permeabil
aceton
triton
wash
cell
block
bovin
serum
albumin
bsa
pb
min
follow
incub
mous
rabbit
antibodi
specif
viral
protein
h
c
repeat
wash
cell
need
incub
fluorescenttag
secondari
antibodi
h
wash
visual
fluoresc
microscop
compar
fluoresc
untreat
drugtreat
cell
altern
quantit
cell
trypsin
treatment
fix
paraformaldehyd
wash
permeabil
label
fluorescenttag
antibodi
follow
propidium
iodid
pi
mgml
pb
count
cell
done
fluorescentactiv
cell
counter
quantit
fluoresc
percentag
measur
pi
indirectli
measur
cytotox
caus
drug
treatment
viru
infect
enzymelink
immunosorb
assay
elisa
solidphas
rapid
sensit
specif
assay
use
qualit
detect
viral
antigen
antibodi
gross
quantit
viru
absolut
quantit
done
seri
predetermin
viral
titer
elisa
match
unknown
sampl
estim
quantiti
viru
untreat
drugtreat
method
differenti
infecti
noninfecti
viru
particl
drug
affect
earlier
later
stage
viral
replic
matur
differenti
briefli
untreat
drugtreat
cell
infect
known
amount
viru
adsorb
h
wash
incub
day
cpe
viru
stock
harvest
freez
thaw
need
centrifug
dilut
elisa
well
plate
coat
virusspecif
antibodi
need
mix
ml
control
test
drug
incub
h
room
temperatur
horseradish
peroxidas
conjug
ml
alkalin
phosphatas
bdgalactosidaselabel
virusspecif
antibodi
wash
five
time
substrat
ml
ad
reincub
dark
min
reaction
stop
stop
solut
h
absorb
read
optic
densiti
od
altern
quadrupl
cell
monolay
plate
overlaid
log
dilut
test
drug
follow
infect
viru
h
incub
c
monolay
fix
glutaraldehyd
assay
virusspecif
protein
cell
surfac
elisa
perform
monoclon
antibodi
specif
protein
correspond
viru
proteina
horseradish
peroxidas
conjug
od
measur
nm
result
express
percentag
virusinfect
cell
viru
control
concentr
caus
reduct
od
plaqu
reduct
assay
phenotyp
assay
use
determin
ic
valu
drug
determin
inhibitor
sensit
eg
neuraminidas
assay
infecti
viru
particl
multipli
form
local
area
infect
cell
plaqu
plaqu
reveal
either
area
deaddestroy
cell
detect
cellular
stain
area
infect
cell
immunostain
figur
protocol
confluent
cell
monolay
cellscm
infect
log
dilut
viral
plaqueform
unit
pfu
presenc
absenc
test
drug
allow
adsorb
h
c
co
cell
wash
twice
prewarm
minimum
essenti
medium
mem
drug
dilut
prepar
overlay
medium
overlaid
infect
cultur
without
test
drug
overlay
medium
compris
memdulbecco
modifi
eagl
medium
dmem
trypsin
mgml
low
melt
agaros
without
serum
test
drug
overlay
medium
ii
compris
ml
mem
supplement
glutamin
ml
antibiot
ml
bicarbon
ml
fb
ml
usual
ml
carboxi
methyl
cellulos
ad
ml
medium
plate
incub
c
co
day
fix
formalin
formaldehyd
min
cell
stain
methylen
blue
ml
well
crystal
violet
wv
rins
tap
water
allow
dri
overnight
plaqu
dark
area
count
low
power
magnif
binocular
microscop
antivir
effect
usual
measur
percentag
inhibit
plaqu
format
mean
number
plaqu
control
mean
number
plaqu
sampl
number
plaqu
control
concentr
test
drug
requir
inhibit
viru
growth
ic
ec
compar
viru
control
estim
graphic
plot
doseerespons
curv
regress
analysi
hemagglutin
activ
ha
assay
quantit
viral
surfac
envelop
hemagglutin
protein
viral
famili
agglutin
stick
human
anim
red
blood
cell
rbc
bind
nacetylneuramin
acid
form
lattic
contrast
plaqu
assay
ha
measur
viral
infect
viru
replic
requir
assay
easi
simpl
rapid
method
larg
sampl
condit
depend
type
viru
virus
bind
rbc
certain
ph
valu
other
certain
ionic
strength
test
drug
inhibit
viru
replic
also
affect
viral
titer
thu
reduc
ha
valu
briefli
viru
dilut
appli
rbc
dilut
min
c
virus
neuraminidas
activ
detach
rbc
latticeform
part
count
calcul
titer
viru
concentrationml
x
ha
titer
protocol
rbc
separ
blood
collect
alseiv
solut
g
dextros
g
sodium
citrat
dihydr
g
sodium
chlorid
g
citric
acid
per
liter
ph
kept
overnight
c
cell
wash
pb
quantiti
cell
pack
ml
blood
yield
ml
pack
measur
suspens
pb
rbc
solut
pb
ml
rbc
ml
pb
ph
ad
well
plate
except
first
well
row
along
antigen
cultur
fluid
contain
viru
drugtreat
untreat
control
first
two
well
row
twofold
dilut
transfer
ml
second
well
column
mix
rbc
ml
well
incub
min
room
temperatur
cell
control
need
check
complet
settl
rbc
result
record
ha
sheet
rbc
form
button
ring
bottom
well
record
hemagglutin
rbc
remain
suspens
record
symbol
highest
dilut
viru
caus
complet
hemagglutin
consid
end
point
ha
titer
reciproc
dilut
viru
last
well
complet
hemagglutin
figur
virus
surfac
ha
protein
influenza
abl
agglutin
rbc
visual
mix
viru
dilut
rbc
thu
use
investig
inhibitori
effect
drug
onto
ha
briefli
serial
dilut
test
drug
along
dilut
viru
stock
use
viru
dilut
mlwell
ad
drugcontain
well
preincub
min
need
mix
rbc
pb
solut
certain
dilut
viral
particl
may
lose
abil
agglutin
rbc
indic
interact
drug
viral
ha
viru
pfuml
etest
drug
mix
usual
incub
h
c
dilut
pfuwel
media
contain
fb
get
subtherapeut
concentr
test
drug
monolay
seed
plate
mix
viru
inoculum
comparison
virusetest
drug
mix
dilut
incub
period
ad
respect
cell
infect
dilut
help
titrat
test
agent
effect
dose
prevent
meaning
interact
host
cell
surfac
adsorpt
h
c
dilut
inoculum
discard
cell
wash
pb
ad
overlay
medium
fb
incub
c
h
subject
plaqu
assay
viral
plaqu
number
obtain
infect
set
presenc
test
drug
compar
control
viral
attach
host
cell
surfac
assay
c
allow
bind
prevent
viral
entri
elisa
briefli
plate
seed
suscept
cell
cellswel
grown
overnight
cell
monolay
chill
c
h
challeng
viru
moi
presenc
test
drug
use
heparin
control
h
c
well
wash
icecold
pb
fix
prechil
paraformaldehyd
pb
h
ice
block
bsa
c
detect
bound
viru
sampl
incub
c
h
primari
antibodi
pbst
pb
tween
plu
bsa
well
wash
twice
pbst
plu
bsa
twice
pbst
interv
shaker
mix
secondari
antibodi
pbst
bsa
incub
c
h
well
wash
develop
tetramethylbenzidin
twocompon
microwel
peroxidas
substrat
min
reaction
stop
phosphor
acid
absorb
read
immedi
nm
valu
express
fold
chang
absorb
rel
mock
infect
control
cell
monolay
grown
plate
chill
c
h
incub
viru
pfuwel
h
c
infect
cell
monolay
reincub
test
drug
heparin
mgml
min
c
facilit
penetr
extracellular
viru
inactiv
citrat
buffer
ph
min
wash
pb
overlaid
dmem
contain
fb
h
incub
c
viral
plaqu
stain
count
plate
cell
cellswel
plate
grown
overnight
confluenc
ad
ml
viru
dilut
deae
dextran
final
concentr
mgml
adsorpt
h
c
co
incub
plate
place
rocker
prevent
cell
dri
fresh
medium
ml
contain
test
drug
ad
well
incub
h
co
c
subconflu
growth
remov
media
fix
solut
ml
ad
well
incub
min
room
temperatur
bgalactosidas
activ
decreas
dramat
fix
solut
left
min
discard
fix
solut
cell
wash
twice
pb
stain
incub
c
min
final
plate
stain
count
number
blue
syncytia
titrat
valu
express
number
stain
cell
multipli
viral
dilut
cell
harbor
viral
subgenom
replicon
usual
maintain
mgml
viral
replicon
cell
seed
plate
incub
c
co
h
cultur
medium
need
replac
medium
contain
serial
dilut
test
drug
fb
dmso
incub
h
total
rna
extract
rna
level
quantifi
quantit
realtim
polymeras
chain
reaction
qrtpcr
use
realtim
pcr
system
specif
primer
dehydrogenas
gene
control
antivir
activ
determin
rna
level
drugtreat
cell
compar
mocktreat
cell
assay
requir
base
pseudoparticl
contain
hcv
vesicular
stomat
viru
vsv
glycoprotein
g
pseudotyp
virus
ad
cell
incub
h
c
mix
test
agent
min
prior
viru
addit
remov
supernat
cell
incub
c
h
measur
luciferas
activ
mechan
action
test
drug
predict
studi
addit
remov
drug
along
inhibit
preinfect
coinfect
postinfect
depict
figur
base
time
test
drug
yield
maximum
inhibit
mechanist
studi
done
target
everi
step
surfac
glycoprotein
fusion
entri
differ
protein
transcript
translat
event
gene
express
separ
use
sever
modern
method
cell
adsorb
microscopyadapt
slide
day
infect
viru
presenc
absenc
test
drug
h
cell
wash
incub
without
polyclon
mgml
antibodi
c
min
rewash
pb
azid
bsa
label
polyclon
mous
antihuman
immunoglobulin
gefluorescein
isothiocyan
fitc
fix
paraformaldehyd
cover
slide
need
mount
mowiol
observ
sequenti
acquisit
use
microscop
planapochromat
numer
apertur
oil
immers
object
optic
section
imag
resolut
pixel
realtim
pcr
wide
accept
viral
load
determin
due
rapid
low
interassay
intraassay
variabl
sensit
reproduc
reduc
risk
carryov
contamin
method
involv
direct
measur
amount
pcr
product
obtain
even
reaction
mathemat
analysi
data
comparison
control
reaction
contain
known
amount
templat
allow
calcul
input
dna
amount
initi
reaction
sever
diseas
correl
well
viral
load
make
realtim
pcr
quantit
use
presenc
viru
also
viral
reactiv
persist
diseas
progress
properti
success
adapt
screen
potenti
antivir
compound
vitro
fold
decreas
viral
genet
materi
presenc
drug
measur
antivir
activ
briefli
cdna
prepar
respect
rna
viru
rt
kit
subject
quantit
realtim
method
valid
antivir
activ
plant
pcr
use
cdna
ml
volum
ml
pcr
core
reagent
kit
primer
probe
use
optimum
concentr
pcr
amplif
carri
per
manufactur
instruct
rnadna
known
viru
serv
posit
control
water
serv
neg
control
amplif
target
dna
detect
pcr
product
perform
sequenc
detect
system
amplif
target
sequenc
detect
increas
fluoresc
baselin
littl
chang
fluoresc
analyz
data
report
fluoresc
automat
normal
passiv
refer
avoid
measur
nonpcrrel
fluoresc
threshold
set
baselin
get
threshold
cycl
valu
ct
cycl
number
fluoresc
pass
fix
threshold
statist
signific
increas
fluoresc
qpcr
amplif
standard
curv
test
agent
design
ct
valu
versu
log
standard
concentr
calcul
interpret
antivir
effect
higher
ct
valu
correspond
drugtreat
sampl
compar
untreat
one
antivir
effect
drug
viral
load
particl
fold
decreas
calcul
standard
plot
ct
valu
less
drugtreat
sampl
untreat
one
data
ic
ic
reduct
viral
particl
fold
chang
may
also
calcul
correspond
cell
line
cellswel
confluenc
infect
five
concentr
log
dilut
pfu
respect
viru
absenc
presenc
test
drug
infect
cell
incub
h
c
co
equal
amount
protein
mgsampl
extract
whole
cell
harvest
buffer
mlwell
contain
mm
tri
ph
ae
mm
nacl
nonyl
deoxychol
doc
ad
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
sdspage
sampl
buffer
heat
c
min
gel
wash
sdspage
run
buffer
load
sampl
run
v
stack
part
v
protein
move
stack
migrat
resolv
gel
blue
dye
front
reach
end
glass
plate
soak
pvdf
membran
methanol
second
distil
water
membran
place
two
fiber
pad
four
whatmann
paper
precut
shallow
tray
fit
transfer
buffer
minut
cut
stack
gel
soak
transfer
buffer
min
gel
transfer
gel
cassett
prepar
transfer
sandwich
cover
insert
gel
cassett
electrod
modul
bioic
cool
unit
buffer
chamber
fill
transfer
buffer
allow
h
c
v
gel
stain
ponge
min
destain
ddh
rins
pb
membran
incub
block
buffer
shaker
h
c
overnight
membran
incub
dilut
primari
antibodi
dilut
buffer
shaker
h
c
overnight
c
wash
four
time
wash
buffer
min
membran
incub
dilut
secondari
antibodi
block
buffer
shaker
h
c
overnight
c
wash
four
time
wash
buffer
min
visual
use
commerci
enhanc
chemiluminesc
western
blot
detect
kit
examin
timedepend
cellular
process
success
exposur
cell
label
compound
puls
unlabel
form
chase
radioact
correspond
cell
line
cellswel
cultur
sixwel
plate
confluenc
infect
five
concentr
log
dilut
viral
pfu
either
absenc
presenc
test
drug
infect
cell
incub
h
c
co
equal
amount
protein
mg
sampl
extract
whole
cell
harvest
buffer
mlwell
contain
mm
tri
ph
ae
mm
nacl
doc
synthes
protein
label
clickit
metabol
label
reagent
cell
transfect
use
h
posttransfect
cell
supernat
replac
fresh
medium
without
mm
fangchinolin
h
cell
need
label
azidohomoalanin
aha
mm
h
methioninefre
medium
without
fangchinolin
supernat
replac
complet
medium
presenc
absenc
fangchinolin
cell
chase
indic
time
lyse
lysi
buffer
mm
tri
hcl
ph
sd
proteas
inhibitor
ahaincorpor
protein
biotinyl
clickinst
protein
reaction
buffer
kit
biotin
alkyn
precipit
dissolut
biotinyl
protein
need
collect
dynabead
myon
streptavidin
purifi
nascent
protein
elut
sdspage
buffer
boil
western
blot
analysi
cell
well
first
dissoci
nonenzymat
cell
dissoci
buffer
infect
viru
moi
presenc
absenc
test
drug
h
c
use
dmso
control
cell
wash
twice
icecold
fluorescenceactiv
cell
sort
fac
buffer
pb
fetal
calf
serum
fc
sodium
azid
need
block
fc
min
ice
stain
fitcconjug
antibodi
wash
fac
buffer
fix
paraformaldehyd
subject
standard
flow
cytometri
analysi
normal
rabbit
serum
serv
isotyp
control
data
acquisit
flow
cytometri
perform
cyan
flow
cytomet
mobil
shift
electrophoresi
gel
band
shift
retard
assay
use
common
affin
electrophoresi
techniqu
studi
proteinedna
proteinerna
interact
determin
whether
protein
mixtur
protein
capabl
bind
given
dna
rna
sequenc
indic
whether
one
protein
molecul
involv
bind
complex
gel
shift
assay
often
perform
studi
transcript
initi
dna
replic
dna
repair
rna
process
matur
oligonucleotid
sequenc
promot
gene
viru
eg
hsv
biotinyl
biotin
end
dna
label
kit
nuclear
extract
virusinfect
cell
treat
test
drug
indic
time
mix
reaction
mixtur
ml
contain
mg
nuclear
extract
fmol
biotin
endlabel
probe
ngml
poli
didc
glycerol
mm
mgcl
bind
buffer
incub
min
room
temperatur
reaction
mixtur
appli
polyacrylamid
gel
trisborateethylenediaminetetraacet
acid
buffer
c
gel
transfer
nylon
membran
use
semi
dri
transfer
cell
biorad
usa
transfer
oligo
immobil
ultraviolet
crosslink
min
detect
bound
oligo
membran
block
block
buffer
follow
addit
streptavidinehorseradish
peroxidas
conjug
develop
accord
manufactur
instruct
supershift
assay
nuclear
extract
preincub
host
cell
polyclon
antibodi
min
ice
small
interf
rna
sirna
silenc
rna
short
bp
doublestrand
rna
nucleotid
transfect
transfer
involv
method
valid
antivir
activ
plant
silenc
gene
sirna
extrem
valuabl
silenc
gene
express
studi
gene
function
usual
correspond
cell
treat
sirna
specif
specif
viral
gene
grown
plate
confluenc
medium
remov
cell
wash
twice
pb
transfect
mixtur
pmol
duplex
sirna
sirna
specif
gene
sirna
lamin
ac
lipofectamin
optimem
incub
min
room
temperatur
ad
well
cell
incub
transfect
mixtur
h
c
co
transfect
medium
replac
fresh
mem
fb
repeat
h
posttransfect
transfect
cell
infect
specif
virus
hour
posttransfect
hpt
perform
immunofluoresc
assay
mention
vitro
antivir
activ
test
drug
valid
vivo
test
specif
model
basi
target
site
infect
diseas
present
variou
anim
model
name
mous
guinea
pig
ferret
rabbit
primat
use
differ
virus
hsv
envelop
doublestrand
dna
viru
classifi
two
type
usual
associ
orolabiali
kerat
enceph
wherea
associ
genit
herp
transmit
close
person
contact
hsv
hide
immun
attack
host
latenc
reactiv
frequent
caus
recurr
episod
moreov
high
risk
factor
acquisit
hiv
infect
recent
report
show
hsvsuppress
therapi
greatli
reduc
load
person
coinfect
hsv
moreov
determin
effect
immun
hsv
infect
yet
identifi
therapeut
vaccin
fail
provid
protect
infect
recurr
henc
broad
spectrum
antivir
natur
origin
import
strategi
manag
hsv
infect
thu
agent
show
antihsv
activ
usual
test
toxic
along
skin
irrit
test
determin
accept
topic
applic
vivo
efficaci
studi
perform
develop
cutan
vagin
ocular
figur
latenc
associ
infect
model
requir
dermal
hypersensit
relat
allerg
manifest
antihsv
agent
alon
ointment
dosag
form
test
batch
mice
specif
dose
test
drugoint
ww
ointment
base
appli
shave
clean
dorsal
area
area
anim
h
residu
ointment
remov
wash
blot
dri
observ
sign
inflamm
red
flash
flare
wheel
correspond
hypersensit
confirm
dermal
toxic
dorsal
hair
femal
mice
shave
hair
remov
cream
clean
luke
warm
water
dri
nake
skin
area
abrad
dermal
sevenstar
needl
appli
g
ointment
desir
abrad
area
cohort
anim
h
ointment
remov
wash
warm
water
anim
examin
erythema
edema
within
anoth
h
anim
also
observ
next
h
addit
confirm
toxic
studi
drug
potenc
cutan
lesion
dorsal
skin
miceguinea
pig
prepar
abrad
abrad
area
divid
four
quadrant
infect
ml
dilut
observ
day
herp
lesion
basi
initi
result
stock
viru
usual
ml
pfu
use
infect
area
consist
lesion
develop
lesion
develop
anim
cohort
n
infect
treat
test
drug
drugbas
ointment
wtwt
acyclovir
ointment
base
g
per
dose
infect
area
steril
cotton
swab
twice
daili
day
figur
extent
lesion
need
score
daili
lesion
onefourth
infect
area
lesion
onehalf
infect
area
lesion
threefourth
infect
area
lesion
entir
infect
area
cotton
rat
test
vivo
efficaci
test
drugformul
genit
herp
model
random
breed
balbc
femal
mice
figur
sigmodon
hispidu
cotton
rat
develop
intravagin
inocul
viru
anesthet
anim
oneweek
acclimat
ae
c
anim
n
dilut
inocul
viru
ml
stock
vagina
needl
size
observ
day
vagin
lethal
ld
test
efficaci
fresh
batch
anim
infect
ld
viru
pfu
follow
inocul
vagin
cotton
swab
sampl
collect
anim
transfer
ml
pb
store
c
anim
divid
test
group
differ
potenc
posit
control
acyclovir
neg
control
solvent
ointment
base
treatment
viru
control
group
along
addit
uninfect
control
group
symptom
viral
vagin
topic
edema
vagin
tract
turbid
secret
observ
third
day
infect
treatment
begin
day
postinfect
appli
test
agent
formul
vagin
tract
cotton
swab
mg
per
mous
twice
daili
day
mortal
number
day
mortal
occur
record
vagin
swab
sampl
collect
day
follow
complet
treatment
well
deceas
anim
immedi
follow
death
figur
vagin
sampl
dilut
five
time
mem
use
infect
vero
cell
sampl
gave
posit
cpe
consid
posit
vagin
inocul
femal
guinea
pig
result
obviou
primari
infect
follow
recoveri
survivor
primari
infect
period
display
vesicular
recrudesc
vagin
area
infecti
viru
andor
viral
dna
recov
although
reactiv
reliabl
induc
spontan
reactiv
much
higher
frequenc
make
attract
model
compar
analysi
influenc
viral
gene
reactiv
hsv
recombin
virus
model
help
investig
identifi
import
featur
differ
valu
guinea
pig
studi
drug
vaccin
effici
experiment
pathogenesi
make
extrem
valuabl
promis
system
fast
simpl
reactiv
model
studi
ocular
herp
viru
infect
latenc
develop
gordon
et
al
new
zealand
femal
rabbit
kg
follow
topic
anesthesia
proparacain
eye
drop
unscarifi
rabbit
eye
inocul
thymidin
kinaseposit
pfuey
lower
fornix
follow
topic
anesthesia
eye
drop
viru
establish
latenc
reactiv
success
inocul
eye
day
produc
herpet
dendrit
ulcer
signific
titer
pfuml
viral
shed
determin
neutral
test
satisfactori
anesthesia
globe
proptos
wooden
cotton
applic
oper
microscop
surgic
manipul
intrastrom
inject
tuberculin
syring
short
bevel
needl
given
central
corneal
stroma
first
group
given
deioniz
steril
endotoxinfre
water
second
group
given
ml
air
group
given
inject
three
group
needl
care
withdrawn
gentl
pressur
proptos
globe
gentli
return
orbit
anterior
chamber
inject
deioniz
steril
water
made
limbu
insert
anterior
chamber
parallel
iri
plane
needl
care
withdrawn
insert
site
press
cotton
swab
avoid
aqueou
loss
return
proptos
globe
proper
place
orbit
topic
administr
ml
deioniz
steril
water
administ
onto
cornea
proptos
globe
mean
pipett
globe
return
orbit
gentl
digit
pressur
viral
shed
latent
reactiv
induc
shed
tear
film
determin
swab
eye
day
treatment
seven
consecut
day
treatment
eye
swab
mix
ml
mem
eagl
medium
earl
salt
newborn
calf
serum
penicillinestreptomycin
fungizon
vortex
eluant
plate
onto
vero
cell
monolay
adsorpt
ml
medium
ad
well
plate
examin
daili
day
cpe
random
isol
confirm
neutral
infect
rabbit
eye
lead
latent
infect
viru
recov
trigemin
nerv
ganglia
follow
explant
cocultiv
indic
cell
addit
viru
sporad
recov
eye
follow
latenc
fact
reactiv
effici
induc
iontophoresi
epinephrin
eye
model
help
establish
latenc
associ
transcript
lat
express
effici
reactiv
second
murin
model
latenc
involv
infect
cornea
follow
latenc
trigemin
ganglia
footpad
model
latent
hsv
genom
express
lat
portion
neuron
maintain
viru
recov
cocultiv
explant
ganglia
interestingli
method
similar
vivo
method
latent
infect
mice
transient
expos
hyperthermia
trigemin
ganglia
excis
section
assay
presenc
observ
viru
immunohistochemistri
genet
engin
recombin
viru
express
marker
genom
use
inbr
femal
balbc
mice
six
eight
week
old
anesthet
intraperiton
inject
ml
ketamin
rompunsolut
rompun
ketamin
solut
mix
pb
infect
intranas
pfu
ml
influenza
viru
infect
influenza
viru
preincub
specif
drug
ml
ml
viru
incub
ml
drug
mgml
ml
pb
min
room
temperatur
eightweekold
balbc
mice
anesthet
use
intraperiton
ip
inject
ketamin
ml
ketamin
solut
xylazin
xylazin
solut
pb
mice
treat
test
drug
use
coaala
mous
aerosol
applic
system
balbc
mice
place
tube
cylind
expos
ml
per
mous
bar
aerosol
test
agent
min
twice
day
lung
titer
day
bodi
weight
along
control
group
h
mice
infect
min
first
exposur
via
intranas
rout
viru
afpv
pfu
recombin
puerto
pfu
ml
volum
determin
viral
replic
lung
monitor
bodi
weight
health
statu
anim
control
twice
day
bodi
weight
measur
everi
day
anim
sacrif
upon
bodi
weight
loss
determin
lung
viru
titer
mous
lung
collect
pb
ml
day
postinfect
pi
homogen
use
homogeniz
lyse
matrix
centrifug
rpm
min
c
supernat
subject
plaqu
assay
bodi
temperatur
gross
motor
activ
anim
monitor
suitabl
softwar
vital
view
hardwar
mini
mitter
usa
data
acquisit
physiolog
paramet
hardwar
includ
transmitt
emitt
receiv
system
collect
data
temperatur
motor
activ
vital
gross
motor
activ
provid
basic
index
movement
mice
implant
emitt
mous
move
movement
implant
emitt
result
subtl
chang
transmit
signal
detect
receiv
regist
comput
vital
view
softwar
record
index
movement
everi
min
produc
longitudin
record
activ
implant
emitt
mice
anesthet
ip
inject
ml
ketaminerompun
shave
ventral
surfac
abdomen
midlin
abdomin
skin
incis
cm
diaphragm
length
abdomen
open
incis
along
linea
alba
posit
emitt
abdomin
caviti
closur
incis
achiev
wound
clip
autoclip
mm
becton
dickinson
germani
anim
place
cage
success
implant
emitt
control
vital
view
softwar
health
statu
control
seven
day
infect
mice
treat
nebul
extract
mgml
three
time
pm
min
h
immedi
treatment
mice
kill
collect
lung
fix
buffer
method
valid
antivir
activ
plant
paraformaldehyd
stain
hematoxylineeosin
lectin
stain
lung
section
perform
sambucu
nigra
agglutinin
sna
vector
laboratori
sialic
acid
link
galactos
maackia
amurensi
agglutinin
mal
ii
vector
laboratori
sialic
acid
link
galactos
secondari
stain
done
abckit
min
room
temperatur
substrat
reaction
diaminiobenzidin
dab
kit
dengu
viru
denv
mosquitoborn
flaviviru
flavivirida
viru
posit
sens
singlestrand
rna
base
code
capsid
protein
c
membran
protein
envelop
protein
e
seven
nonstructur
short
noncod
region
end
classif
serotyp
genotyp
often
relat
region
particular
strain
found
inhibitori
potenti
test
drug
evalu
suckl
mice
briefli
serial
twofold
dilut
test
agent
mix
ld
viru
equal
proport
incub
h
room
temperatur
incub
ml
mixtur
viru
drug
per
mous
pup
inocul
intracerebr
along
viru
mice
control
observ
daili
sign
dengu
weight
loss
slow
gait
inabl
suck
mother
milk
flaccid
paralysi
follow
death
postinocul
day
mous
pup
collect
kill
chloroform
inhal
store
c
rna
extract
addit
preincub
inhibit
assay
pretreat
posttreat
test
drug
attempt
per
protocol
except
time
drug
addit
vari
rtpcr
order
demonstr
presenc
absenc
viral
rna
infect
cell
mous
brain
rtpcr
perform
employ
group
specif
primer
briefli
rna
extract
elut
subject
rtpcr
initi
revers
transcript
moloney
murin
leukemia
viru
reversetranscriptas
mmlvrt
synthes
cdna
cdna
synthesi
usual
carri
volum
rtmix
rt
buffer
mm
dntp
rnasin
mmlvrt
c
h
use
downstream
consensu
primer
amplif
cdna
carri
pcr
ml
volum
conga
pcr
mix
buffer
mm
mm
dntp
u
taqdna
polymeras
use
upstream
consensu
primer
dna
thermal
cycler
thermal
profil
pcr
reaction
includ
initi
denatur
c
min
follow
cycl
denatur
c
anneal
c
min
extens
c
min
final
extens
c
min
amplifi
product
analyz
agaros
gel
presenc
bp
virusspecif
amplicon
exist
viral
diseas
fatal
also
upsurg
new
viral
infect
worldwid
current
avail
antivir
though
effect
costli
beyond
reach
vast
major
peopl
thu
develop
safe
effect
low
cost
antivir
drug
rt
inhibitor
among
top
prioriti
mani
virus
yet
curabl
high
mortal
rate
recent
consider
work
done
medicin
plant
focus
antihiv
activ
consider
rise
use
overthecount
plant
product
contain
orthodox
drug
rational
reduc
side
effect
produc
synergist
effect
sinc
case
pharmacolog
mechan
combin
studi
advers
effect
therapeut
failur
observ
import
consider
involv
medicin
plant
identifi
standard
method
prepar
extract
appropri
season
collect
plant
materi
detail
administr
sinc
signific
number
plant
extract
yield
posit
result
seem
reason
conclud
probabl
mani
potenti
antivir
agent
character
activ
ingredi
potenti
plant
reveal
use
compound
